Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomized, Open Label, Blinded-Endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM [ambulatory blood pressure monitoring] in Subjects With Mild-to-Moderate Essential Hypertension.

Next Previous
X
Search
Trial Profile

Prospective, Randomized, Open Label, Blinded-Endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM [ambulatory blood pressure monitoring] in Subjects With Mild-to-Moderate Essential Hypertension.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramipril (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms HYCCRA

    • Most Recent Events

    • 10 Sep 2009 Actual patient number changed from 115 to 120 as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Results published in Hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top